Q-Med AB

Development, production, commercialization of medical implants

Q-Med started in 1987 with the aim to realise the ideas of its founder, Bengt Ågerup,and offered in 1996 their first product based on own technology.
Today the company has approximately 540 coworkers and a production facility located in Uppsala.

The Q-Med share is listed on the O-list of the Stockholm Stock Exchange.

Bengt Ågerup,PhD, Founder, President, CEO
Erika Kjellberg Eriksson, Vice President, CFO
Cindy Wong, CMO, Head of Medical Affairs

Pia Rudengren, Chairman
Håkan Edström
Bertil Hult
Anders Milton
Åsa Rödén
Pernilla Ström
Bengt Ågerup

Seminariegatan 21
752 28 Uppsala
Sweden
Phone: +46 18-474 90 00
Fax: +46 18-474 90 01

The achievement of Q-Med grounds on the proprietary technology NASHA (Non-animal stabilised hyaluronic acid).

This technology is the basis of the company’s products used to treat wrinkels as well as osteoarthritis of the knee and hip (Duralone®), vesicoureteral reflux in children (Deflux®) or stress urinary incontinence in women (Zuidex™).

Q-Med has also initiated several studies, including the testing of Macrolane for minor breast augmentations.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.